New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
November 9, 2012
17:07 EDTCELGCelgene study shows ABRAXANE improves survival for pancreatic cancer patients
Celgene International Sarl, a subsidiary of Celgene Corporation, announced that its phase III study of ABRAXANE, a paclitaxel protein-bound particles for injectable suspension, in combination with gemcitabine in treatment-naive patients with advanced pancreatic cancer met its primary endpoint of overall survival. In the study, ABRAXANE in combination with gemcitabine demonstrated a statistically significant improvement in overall survival compared to patients receiving gemcitabine alone. The primary endpoint for the study is improvement in overall survival. Secondary endpoints include evaluation of progression-free survival, objective tumor response and the safety and tolerability of this combination in this patient population. The safety profile of ABRAXANE in combination with gemcitabine observed in the study is comparable with other ABRAXANE clinical trials in pancreatic cancer. Based on the results of the MPACT study, the company plans to submit dossiers for registration in the US, Europe and other markets. ABRAXANE is not currently approved for the treatment of advanced pancreatic cancer.
News For CELG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 22, 2015
13:21 EDTCELGAlphabet, Celgene, others could rise 20% over next year, Barron's says
Subscribe for More Information
November 20, 2015
10:52 EDTCELGFDA approves new oral medication to treat multiple myeloma
Subscribe for More Information
November 17, 2015
08:22 EDTCELGSignificant Celgene overhang removed, says JMP Securities
Subscribe for More Information
November 16, 2015
13:11 EDTCELGCelgene jumps 2% after defeating Kyle Bass patent challenge
Shares of Celgene moved higher after the U.S. Patent and Trademark Office declined to review a Revlimid patent expiring in 2019. The USPTO found that that Bass's Coalition for Affordable Drugs was unlikely to succeed, according to Bloomberg. Shares of Celgene are up 2%, or $1.64, to $190.13 in afternoon trading. The agency is reviewing two other patents on the drug.
13:08 EDTCELGCelgene defeats Bass challenege on Revlimid patent, Bloomberg reports
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use